Printer Friendly

CORDIS SAYS FDA RULES AGAINST ADDITIONAL INFORMATION

 CORDIS SAYS FDA RULES AGAINST ADDITIONAL INFORMATION
 MIAMI, June 10 /PRNewswire/ -- Cordis Corporation


(NASDAQ-NMS: CORD) today announced that the Food and Drug Administration (FDA) has decided not to invoke section 518(a) of the Food, Drug and Cosmetic Act in response to the company's recent voluntary recall of certain valves used in the treatment of hydrocephalus.
 The proposed action, which Cordis first reported May 11, would have required far greater notification of physicians and patients than is generally the case in recalls of this type.
 Robert C. Strauss, president and chief executive officer, praised the FDA for "considering the statements of a medical expert, as well as other data, indicating that special notification was unnecessary." The agency's action, he said, is gratifying to the company and the medical community.
 Miami-based Cordis Corporation manufactures and markets a variety of medical devices and systems for the angiographic and neuroscience markets. Shares of the company's stock are traded on the NASDAQ National Market under the symbol CORD.
 -0- 6/10/92
 /CONTACT: Chick McDowell, vice president of corporate relations and assistant secretary of Cordis Corporation, 305-824-2821/
 (CORD) CO: Cordis Corporation ST: Florida IN: HEA SU:


AW-JB -- FL002 -- 8677 06/10/92 09:09 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 10, 1992
Words:201
Previous Article:YOUTH WORK PROGRAM RECEIVES BOOST AS CONSUMERS POWER COMPANY LEASES TIPPY DAM CONFERENCE CENTER TO STATE OF MICHIGAN
Next Article:ROBERT J. MASSIE NAMED DIRECTOR OF CHEMICAL ABSTRACTS SERVICE
Topics:


Related Articles
CORDIS REPORTS SEC FILINGS
CORDIS' THIRD QUARTER NET INCOME UP 19 PERCENT
CORDIS RECEIVES LETTER FROM FDA
CORDIS MAGNETIC RAPID-EXCHANGE SYSTEM GAINS FDA APPROVAL
FDA Approves New Cordis Rapid Exchange Delivery System For Increased Versatility of its Bx Velocity(TM) Coronary Stent.
Cordis Cardiology Issues Statement Regarding GMP Observations.
Cordis Corporation's Drug-Eluting Stent Receives Unanimous Recommendation From FDA Advisory Panel.
Cordis Announces Nationwide Recall of Revised Instructions for Use for the PRECISE(R) RX Biliary Stent Contained in Its Medical Device Notification...
FDA Approves Updated Instructions for Use for the CYPHER(R) Sirolimus-Eluting Coronary Stent.
Cordis Corporation Resolves Corporate Warning Letter.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters